Andrew is an experienced finance professional with 18 years of experience working across the globe in multi-disciplinary roles and varied industries. Andrew was the CFO of Avance Clinical and Agilex Biolabs during the COVID pandemic, where he developed a deep understanding of the life sciences industry and working with biotechs from all over the world.

Andrew also consults to other life sciences companies and has invested in biotechs over time. Andrew is a Chartered Accountant and is very keen to support biotechs with their growth strategies, commercialisation objectives, financial modelling and can lend assistance with governance and board reporting. 

Dr. Glenn Haifer has over 30 years’ experience in the healthcare sector. He has successfully built businesses in the health care services and life sciences industries in Australia, which he has exited through sales to private equity and ASX-listed companies.

Doron has a background in strategy consulting and finance, where he has worked across multiple industries including healthcare and life sciences. He previously worked at Boston Consulting Group, a leading global consulting firm.

Doron has experience in financial modelling, building business cases and establishing board reporting which he hopes to use to assist Endpoints Capital’s clients.

With over 20 years of pharmaceutical and research experience, Holly is a seasoned executive who leverages her global knowledge of drug development across nonclinical and clinical trials, including regulated bioanalysis and toxicology services across multiple species.

Prior to joining Endpoints Capital, Holly was CCO of Agilex Biolabs and has experience in Phase 0-IV across multiple indications, with a primary focus on early phase clinical development in Australia & New Zealand. She has held various leadership roles, including working in Quintiles phase I clinical research unit in Overland Park, Kansas, director of clinical operations in small oncology biotech, and in 2018 transferred to Sydney, Australia with IQVIA where she has extensive knowledge in guiding emerging biotechs in US, APAC and EU to navigate the requirements for conducting clinical trials in Australia.

Patrick is an experienced finance professional with a background in accounting, taxation and corporate finance. Patrick has previously worked at PwC for a broad range of clients in a variety of industries and for Santos Ltd in the accounting and finance function. 

Patrick is a Chartered Accountant and manages the finance operations of Endpoints Capital, whilst also assisting clients to find the right solution for their funding needs.

Daniel is currently studying a Bachelor of Finance, Economics and Statistics (Honours) at the Australian National University on a Tuckwell Scholarship. With a strong passion for finance and mathematics, Daniel is well-equipped to support Endpoints Capital’s credit assessment process.

Charlie is currently studying a Bachelor of Commerce and Bachelor of Advanced Studies at The University of Sydney. Charlie gained experience in Investment Banking at Allier Capital, and in Private Equity at Pemba Capital Partners, from which he developed strong financial acumen and analytical skills, as well as a deep understanding of the healthcare industry, all of which support his execution of credit and business analysis at Endpoints Capital.